Efficacy and Safety of Helical Tomotherapy Combined With Paclitaxel in Cutaneous Angiosarcoma
Clinical Summary
View sourceWhat was studied
Retrospective review of 12 patients with cutaneous angiosarcoma treated with helical tomotherapy plus paclitaxel between January 2017 and April 2024, assessing progression-free survival, overall survival, and adverse events, with comparison to historical controls.
Key findings
Median progression-free survival was 10.5 months (95% CI, 7.7–not reached). Two-year overall survival and progression-free survival rates were 70.0% and 41.7%, respectively; grade ≥3 adverse events included radiation dermatitis (n=1), neutropenia (n=2), peripheral neuropathy (n=1), and corneal toxicity (n=1).
Study limitations
Very small sample size (n=12) and retrospective design; outcomes were compared only with historical controls without a concurrent comparator.
Clinical implications
When using tomotherapy with paclitaxel for cutaneous angiosarcoma, clinicians can counsel that this series observed a 2-year overall survival of 70% and limited grade ≥3 toxicities, while emphasizing the evidence is from a small retrospective cohort.
Related Questions
Explore related topics and deepen your understanding